{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ngoi NYL"],"funding":["National Medical Research Council (NMRC)","Indian Institute of Science Education and Research Mohali","Indian Institute of Science Education and Research Mohali (IISER)","AstraZeneca (AstraZeneca PLC)","National Medical Research Council","AstraZeneca","Pangestu Family Foundation Gynaecological Cancer Research Fund"],"pagination":["3907-3915"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12440240"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(18)"],"pubmed_abstract":["<h4>Purpose</h4>The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.<h4>Patients and methods</h4>MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.<h4>Results</h"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial."],"pmcid":["PMC12440240"],"funding_grant_id":["CSASI21jun-0003","NMRC/MOHIAFCat1/0061/2016"],"pubmed_authors":["Ow SGW","Chay WY","Choi CH","Lim YW","Tan TZ","Heong V","Lim SE","Kim K","Kim HS","Ngoi NYL","Kim JW","Goh JC","Tan DSP","Friedlander M","Zhu J","Lim D","Goss G","Tai BC","Sun H"],"additional_accession":[]},"is_claimable":false,"name":"Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.","description":"<h4>Purpose</h4>The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.<h4>Patients and methods</h4>MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.<h4>Results</h","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-02T05:26:40.744Z","creation":"2026-04-14T03:14:12.882Z"},"accession":"S-EPMC12440240","cross_references":{"pubmed":["40705396"],"doi":["10.1158/1078-0432.CCR-25-0201"]}}